Spero Therapeutics Inc (SPRO) — Cash Flow Quality Index
Spero Therapeutics Inc (SPRO) has a Cash Flow Quality Index of -0.26x as of December 2025. Operating cash flow of $-8.35 Million is below net income of $31.52 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore SPRO cash flow metrics to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Spero Therapeutics Inc Cash Flow Quality Index (2023–2025)
Historical Cash Flow Quality Index for Spero Therapeutics Inc across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Spero Therapeutics Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Spero Therapeutics Inc (2023–2025)
Year-by-year earnings quality comparison for Spero Therapeutics Inc. For live market cap and the full company financial profile, see Spero Therapeutics Inc (SPRO) market capitalisation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -1.47x | $-12.62 Million | $8.57 Million | ▼ -1.8% |
| 2023 | -1.45x | $-32.99 Million | $22.81 Million | — |